查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933355

全球轮状病毒疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量、未来预测（2026-2034）

Rotavirus Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

轮状病毒疫苗市场成长驱动因素

2025年全球轮状病毒疫苗市场规模为52.2亿美元，预计2026年将成长至55.7亿美元，到2034年将达到128.6亿美元，复合年增长率高达11.03%。北美地区在2025年占市场主导地位，市占率为8.53%。这得归功于先进的医疗基础设施、完善的疫苗接种计划以及公众对轮状病毒感染的高度认知。轮状病毒是一种高度传染性的病毒，主要感染胃肠道，是婴幼儿严重腹泻和呕吐的主要原因之一。 接种疫苗（通常作为常规免疫接种计划的一部分口服）是最有效的预防措施。

市场动态

驱动因素：市场成长的主要驱动因素是各国免疫规划的不断扩大，特别是在东南亚、欧洲和北美地区。美国、德国和法国等国家已将轮状病毒疫苗纳入儿童常规免疫接种计画。例如，印度国家免疫技术咨询委员会 (NTAGI) 于 2019 年建议将轮状病毒疫苗纳入全民免疫规划 (UIP)。此外，人们对轮状病毒感染的认识不断提高，以及联合国儿童基金会 (UNICEF) 和全球疫苗免疫联盟 (Gavi) 等国际组织的支持措施，也进一步推动了市场成长。

限制因素：供应链挑战是市场扩张的障碍。轮状病毒疫苗需要严格的冷链储存和运输，供应中断可能促使暂时性短缺，并需要使用替代疫苗。 联合国儿童基金会2024年报告称，葛兰素史克公司在2022年至2023年间的供应中断迫使一些国家转向替代产品，影响了疫苗的普及率。

机会：扩大疫苗接种覆盖范围带来了成长机遇，尤其是在印度和中国等发展中国家。加强政府主导的措施以及将轮状病毒疫苗纳入国家免疫规划，预计将推动疫苗接种覆盖率和市场成长。 2024年，乍得在其扩大免疫规划（EPI）下引入了轮状病毒、疟疾和肺炎球菌疾病疫苗，这反映了全球扩大疫苗接种覆盖范围的趋势。

挑战：疫苗安全问题，例如肠套迭（一种罕见的肠阻塞），可能会影响大众认知并阻碍市场成长。根据美国疾病管制与预防中心2024年的数据，研究显示接种疫苗后肠套迭的风险略有增加，凸显了有效疫苗安全沟通的必要性。

市场趋势

疫苗递送方式的创新，例如可溶性贴片和新型注射配方，是一个显着的趋势。口服疫苗虽然方便，但由于酵素降解和首过效应，其生物利​​用度较低。 2025年，埃默里大学和美光生物医学公司启动了第一个轮状病毒疫苗 "CC24" 的临床试验，该疫苗采用可溶性微阵列技术。这些进展凸显了疫苗递送方式正朝着更有效、更人性化的方向发展。

细分市场分析

依类型划分：减毒活疫苗因其强效且持久的免疫反应而占市场主导地位。 FDA核准的RotaTeq和RotaTeq疫苗是市场对减毒活疫苗依赖性的典型例证。 次单位疫苗，例如SK Chemicals的三价P2-VP8次单位疫苗，预计将推动未来的成长。

依产品划分：RotaTeq占市场占有率领先地位，可预防五种轮状病毒株，并已被纳入国家免疫规划，以降低住院率和死亡率。 ROTARIX凭藉其高效能性和在北美、欧洲和亚太等主要地区的核准，保持显着的市场地位。

分销管道：政府供应商占主导地位，特别是透过像印度的全民免疫计划（UIP）这样的项目，该计划确保免费获得疫苗并扩大疫苗接种覆盖范围。 由于轮状病毒病例和患者数量的增加，医院和零售药局也做出了显着贡献。

区域展望

北美：预计到2025年，市场规模将达到20.3亿美元，到2026年将达到21.9亿美元。这一增长得益于先进的医疗基础设施、高疫苗接种率和研发能力。

欧洲：自2006年Rotarix和RotaTeq获批上市以来，欧洲市场已占显着的市场占有率，降低了因轮状病毒性肠胃炎促使的住院率（每年7.5万至15万例）。

亚太地区：该地区正经历最快的成长，这主要得益于庞大的儿童人口、政府主导的举措以及公众意识的提高。在东南亚，轮状病毒感染占儿童腹泻病例的40.8%。

拉丁美洲、中东和非洲：政府主导的措施以及全球疫苗免疫联盟（Gavi）和联合国儿童基金会等组织的支持，正透过低成本疫苗帮助提高疫苗覆盖率，从而实现稳步增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 轮状病毒感染发生率/盛行率（2025 年）
  • 主要公司新产品发布
  • 主要公司产品线分析
  • 轮状病毒疫苗接种建议/指南
  • 轮状病毒疫苗接种计画概述
  • 轮状病毒疫苗技术进展
  • 主要产业趋势：併购、业务合作等

第五章 全球轮状病毒疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 减毒活疫苗
    • 其他
  • 市场分析、洞察与预测：依产品划分
    • Rotarix
    • RotaTeq
    • Rotasil
    • Rotovac
    • 其他
  • 市场分析、洞察与预测：依通路划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美轮状病毒疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲轮状病毒疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章 亚太地区轮状病毒疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲轮状病毒疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲轮状病毒疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家/地区
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • GSK plc
    • Merck &Co. Inc.
    • Serum Institute of India Pvt. Ltd.
    • Sanofi
    • Bharat Biotech
    • SINOVAC
Product Code: FBI113730

Growth Factors of rotavirus vaccines Market

The global rotavirus vaccines market was valued at USD 5.22 billion in 2025 and is projected to grow to USD 5.57 billion in 2026, reaching USD 12.86 billion by 2034, exhibiting a strong CAGR of 11.03%. North America dominated the market in 2025, with a market share of 8.53%, driven by advanced healthcare infrastructure, robust vaccination programs, and strong public awareness about rotavirus infections. Rotavirus, a highly contagious virus affecting the gastrointestinal tract, is a leading cause of severe diarrhea and vomiting in infants. Vaccination, usually administered orally as part of routine immunization schedules, is the most effective preventive measure.

Market Dynamics

Drivers: A major factor driving market growth is the increasing adoption of national immunization programs, particularly in Southeast Asia, Europe, and North America. Countries like the U.S., Germany, and France have integrated rotavirus vaccines into routine childhood immunizations. For instance, in India, the National Technical Advisory Group on Immunization (NTAGI) recommended including the rotavirus vaccine in the Universal Immunization Programme (UIP) in 2019. Additionally, rising awareness of rotavirus infections and supportive initiatives by international organizations, such as UNICEF and Gavi, are further bolstering market growth.

Restraints: Supply chain challenges pose a constraint on market expansion. Rotavirus vaccines require strict cold-chain storage and transport, and disruptions can lead to temporary shortages or the use of alternative vaccines. UNICEF reported in 2024 that several countries had to switch to alternative products due to supply disruptions from GSK in 2022-2023, which impacted adoption rates.

Opportunities: Expanding vaccination coverage offers growth opportunities, particularly in developing countries such as India and China. Increased government initiatives and inclusion of rotavirus vaccines in national immunization schedules are expected to raise vaccine uptake and market growth. In 2024, Chad introduced vaccines for rotavirus, malaria, and pneumococcal infections under the Expanded Programme on Immunization, reflecting a global trend toward broader preventive coverage.

Challenges: Vaccine safety concerns, such as intussusception (a rare bowel obstruction), may influence public perception and hinder market growth. According to CDC data in 2024, studies indicate a slight increase in intussusception risk post-vaccination, emphasizing the need for effective communication on vaccine safety.

Market Trends

Innovation in vaccine delivery, such as dissolvable patches and novel parenteral formulations, is a prominent trend. Oral vaccines, while convenient, have low bioavailability due to enzymatic degradation and first-pass metabolism. In 2025, Emory University and Micron Biomedical initiated the first clinical trial of CC24, a rotavirus vaccine delivered via dissolvable microarray technology. Such developments highlight the ongoing shift toward more effective and patient-friendly vaccine delivery methods.

Segmentation Analysis

By Type: The live attenuated vaccine segment dominates due to strong, long-lasting immune responses. FDA-approved vaccines like ROTARIX and RotaTeq exemplify the market's reliance on live attenuated formulations. Subunit vaccines, such as the trivalent P2-VP8 candidate by SK Chemicals, are under development and expected to drive future growth.

By Product: RotaTeq holds the leading share, protecting against five rotavirus strains and included in national immunization programs, reducing hospitalization and mortality. ROTARIX remains significant due to its high potency and approval across major regions, including North America, Europe, and Asia Pacific.

By Distribution Channel: Government suppliers dominate, particularly through programs like India's UIP, ensuring free vaccine access and expanding coverage. Hospitals and retail pharmacies contribute significantly due to increasing rotavirus cases and high patient flow.

Regional Outlook

North America: Market valued at USD 2.03 billion in 2025, projected to reach USD 2.19 billion in 2026, led by advanced healthcare infrastructure, high vaccination rates, and R&D capabilities.

Europe: Holds a substantial share, supported by ROTARIX and RotaTeq approvals since 2006, reducing hospitalization rates from rotavirus gastroenteritis (75,000-150,000 annually).

Asia Pacific: Fastest-growing region due to large pediatric populations, government initiatives, and rising awareness. Rotavirus accounts for 40.8% of diarrheal diseases in Southeast Asian children.

Latin America & Middle East & Africa: Expected to grow steadily due to government initiatives and support from organizations like Gavi and UNICEF, which provide vaccines at low cost to improve coverage.

Competitive Landscape

The market is concentrated, with key players including GSK plc., Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Sanofi, Bharat Biotech, and SINOVAC. Companies focus on product innovation, distribution partnerships, and R&D investments. For example, GSK received FDA approval in 2022 for a new liquid ROTARIX vaccine, and Merck expanded RotaTeq supply to China in 2018, demonstrating strategic market positioning.

Conclusion

The global rotavirus vaccines market is poised for significant growth, from USD 5.22 billion in 2025 to USD 5.57 billion in 2026, and reaching USD 12.86 billion by 2034 at a CAGR of 11.03%. Growth is driven by national immunization programs, increasing pediatric populations, innovative vaccine formulations, and government initiatives supporting equitable vaccine access. North America remains a dominant region, while Asia Pacific emerges as the fastest-growing market. Despite challenges like supply chain disruptions and safety concerns, robust R&D and expansion of vaccination coverage are expected to sustain market momentum over the forecast period.

Segmentation By Type

  • Live Attenuated
  • Others

By Product

  • ROTARIX
  • RotaTeq
  • ROTASIIL
  • ROTOVAC
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America (By Type, Product, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Type, Product, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Product, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • South Korea
    • Rest of Asia Pacific
  • Latin America (By Type, Product, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Product, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Rotavirus Infection, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Recommendations/Guidelines for Rotavirus Vaccines
  • 4.5. Overview: Vaccination Schedule for Rotavirus
  • 4.6. Technological Advancements in the Rotavirus Vaccines
  • 4.7. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Live Attenuated
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. ROTARIX
    • 5.2.2. RotaTeq
    • 5.2.3. ROTASIIL
    • 5.2.4. ROTOVAC
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Live Attenuated
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. ROTARIX
    • 6.2.2. RotaTeq
    • 6.2.3. ROTASIIL
    • 6.2.4. ROTOVAC
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Live Attenuated
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. ROTARIX
    • 7.2.2. RotaTeq
    • 7.2.3. ROTASIIL
    • 7.2.4. ROTOVAC
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Live Attenuated
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. ROTARIX
    • 8.2.2. RotaTeq
    • 8.2.3. ROTASIIL
    • 8.2.4. ROTOVAC
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Live Attenuated
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. ROTARIX
    • 9.2.2. RotaTeq
    • 9.2.3. ROTASIIL
    • 9.2.4. ROTOVAC
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Rotavirus Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Live Attenuated
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. ROTARIX
    • 10.2.2. RotaTeq
    • 10.2.3. ROTASIIL
    • 10.2.4. ROTOVAC
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital & Retail Pharmacies
    • 10.3.2. Government Suppliers
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck & Co. Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Serum Institute of India Pvt. Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Bharat Biotech
      • 11.2.5.1. Overview
      • 11.2.5.2. Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. SINOVAC
      • 11.2.6.1. Overview
      • 11.2.6.2. Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 3: Global Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 7: North America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 11: Europe Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 15: Asia Pacific Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 19: Latin America Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: Middle East & Africa Rotavirus Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Rotavirus Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Rotavirus Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Rotavirus Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Rotavirus Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 4: Global Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Rotavirus Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 8: North America Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 10: North America Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Rotavirus Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Rotavirus Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 16: Europe Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 17: Europe Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 18: Europe Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Rotavirus Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Rotavirus Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 25: Asia Pacific Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 26: Asia Pacific Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Rotavirus Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Rotavirus Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Latin America Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 34: Latin America Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Rotavirus Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Rotavirus Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Rotavirus Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Rotavirus Vaccines Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Rotavirus Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 41: Middle East & Africa Rotavirus Vaccines Market Value Share (%), by Product, 2025
  • Figure 42: Middle East & Africa Rotavirus Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Rotavirus Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Rotavirus Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Rotavirus Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Rotavirus Vaccines Market Share (%), By Company, 2025